Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
- Terry's Desk
- 45 minutes ago
- 5 min read
Many pharmacology experiments produce beautifully clean assay curves. Potency estimates appear precise, maximal responses align neatly, and screening data generates clear rank orderings of compounds.
The harder question is what those assay signals actually predict biologically.
Drug discovery programs rarely fail because an assay produced poor data. They fail because the interpretation of that data did not translate to biology outside the assay system.
Pharmacology exists precisely to bridge that gap. It creates conceptual scales that allow scientists to project observations from one experimental system into another.
During a recent AMA discussion, several experienced scientists raised questions about assay scaling, pharmacokinetics, and discovery decision-making. Dr. Kenakin used those questions to explore how pharmacological reasoning turns experimental signals into actionable insight.
In this session, you’ll gain:
How pharmacology translates assay signals into biological predictions
Why EC₅₀ values rarely capture the full pharmacological picture
How binding kinetics and PK considerations influence discovery decisions
Drug Discovery Pharmacology Principles in Action
Drug discovery pharmacology principles revolve around one core idea: translation.
Chemistry identifies molecules. Biology reveals targets. But pharmacology asks a different question:
How will this molecule behave in a system we have not yet tested?
That predictive step is essential because discovery scientists almost always operate inside partial models of biology.
Key realities pharmacologists face:
Assays measure one slice of biology
Disease physiology involves many interconnected systems
Drug concentrations constantly rise and fall in vivo
Pharmacology therefore constructs conceptual scales—linking ligand binding, receptor activation, and downstream signaling—to project how molecules behave beyond the assay.
As Dr. Kenakin explains, pharmacology differs from other life sciences precisely because it builds quantitative frameworks that allow projection from one system to another.
The Assay Window Problem
Every functional assay operates within a measurement window, and interpreting results requires understanding how responses scale within that window.
Consider calcium flux assays:
Teams often ask how to define fractional receptor activation, similar to how forskolin establishes maximal cAMP signaling.
Practical strategies include:
Using known controls (e.g., ATP or carbachol) to define maximal signal
Normalizing agonist responses to a common reference window
Accepting that maximal response may be estimated rather than exact
In practice, the precise maximal signal matters less than many assume. When responses are scaled consistently, comparisons remain meaningful even if the absolute maximum is imperfect.
As Dr. Kenakin notes, much of the interpretive power comes from the EC₅₀ component of the response, while small differences in maximal signal contribute relatively little to the overall interpretation.
EC₅₀ Misconceptions Persist
Few misunderstandings derail discovery programs faster than misinterpreting EC₅₀.
Even experienced biologists sometimes treat EC₅₀ as if it reflects ligand affinity. In reality, it represents something very different:
EC₅₀ is a system-dependent measure of functional response.
It reflects:
receptor density
signaling efficiency
assay sensitivity
downstream amplification
Not simply ligand binding.
This distinction becomes especially important when comparing mutants, partial agonists, or signaling pathways.
A ligand may show identical EC₅₀ values in two assays while engaging receptors through very different mechanisms.
Understanding this distinction allows teams to:
interpret pharmacological differences across systems
normalize mutant receptor data
avoid misleading potency comparisons
Dr. Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes even when expression levels vary.
Time Matters More Than Potency
For decades, discovery teams prioritized potency above all else.
The logic seemed obvious:
Higher potency → lower dose → fewer side effects.
But this assumption misses a crucial pharmacological reality: biological systems operate in time, not equilibrium.
Drug concentrations constantly change as molecules:
distribute through tissues
bind and unbind receptors
undergo metabolism and clearance
This dynamic environment makes residence time—how long a ligand stays bound to its receptor—critically important.
Two compounds with identical potency may behave very differently in vivo if one remains bound longer.
Dr. Kenakin highlights that therapeutic efficacy depends on the period during which a drug is actively engaged with its target, not simply how strongly it binds at equilibrium.
When PK Ends Programs
Discovery teams often fall in love with molecules that show beautiful activity in vitro.
But pharmacology introduces a sobering truth:
A drug that cannot reach its target is not a drug.
Pharmacokinetics—absorption, distribution, metabolism, and excretion—must therefore be addressed early.
Common PK deal breakers include:
poor solubility preventing absorption
rapid clearance eliminating exposure
sequestration in tissues or proteins
One classic example occurs when compounds dissolve poorly, behaving essentially like inert particles within biological systems.
Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo.
The good news is that modern technologies—from delivery systems to alternative dosing routes—are dramatically expanding the options available to rescue promising scaffolds.
Dr. Kenakin discusses how discovery teams balance enthusiasm for biological activity with the practical constraints of pharmacokinetics.
Chemists Make The Drugs
Drug discovery is fundamentally a team sport.
Pharmacologists interpret biological data. But chemists transform that data into molecules capable of becoming medicines.
Kenakin often recalls advice from Nobel laureate James Black:
Chemists make the drugs. Your job as a pharmacologist is to guide them with solid data.
This relationship defines productive discovery teams.
Pharmacologists contribute:
rigorous assay interpretation
mechanistic insight into receptor signaling
quantitative frameworks for decision making
Chemists contribute:
structural creativity
scaffold optimization
elimination of toxic chemical features
Experienced chemists, for example, instinctively avoid known toxicophores—chemical groups associated with safety liabilities.
When both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular design toward viable drug candidates.
Failure Is the Real Curriculum
Drug discovery carries a difficult truth: most programs fail.
Even promising molecules collapse due to safety issues, pharmacokinetics, or unexpected
biology.
Yet failure is not a sign of weakness in discovery science. It is the mechanism by which progress occurs.
Kenakin summarizes the mindset required with a quote attributed to Winston Churchill:
Success is the ability to go from failure to failure without loss of enthusiasm.
For scientists entering drug discovery, the lesson is simple:
most hypotheses will be wrong
most compounds will fail
persistence is essential
But the iterative process—assay, interpretation, redesign—ultimately produces the breakthroughs that transform medicine.Dr. Kenaking reveals how experienced pharmacologists turn repeated failures into increasingly powerful insights.
Why Terry’s Corner
Drug discovery pharmacology principles rarely appear in textbooks the way they are practiced in industry.
Terry’s Corner was created to close that gap.
Subscribers gain access to:
Weekly pharmacology lectures by Dr. Terry Kenakin
Monthly live AMAs with real discovery questions
A growing on-demand library of practical pharmacology insights
The Corner is built for:
pharmacologists refining core analytical tools
discovery teams navigating development bottlenecks
scientific leaders seeking clear pharmacological guidance
GPCR innovation is accelerating rapidly. The scientists who strengthen their pharmacology foundations today will define tomorrow’s breakthroughs.
Comments